Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Episcleral Dexamethasone for Macular Edema
NCT04120311Phase 1Active, not recruiting
- Sponsor
- Targeted Therapy Technologies
- Start
- Sep 2019
- Primary completion
- Sep 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dexamethasone in macular edema, posterior uveitis, radiation retinopathy (RR) and 4 more, sponsored by Targeted Therapy Technologies. Primary endpoint: Ocular Safety Assessment at 12 months. Started Sep 2019; status: active, not recruiting.
02
Drugs
dexamethasone
03
Conditions
macular edemaposterior uveitisradiation retinopathy (RR)retinal vein occlusion (RVO)Central Serous Chorioretinopathy (CSCR)
Beyond the preview
Go deeper on NCT04120311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04120311.